Copley Scientific has announced the launch of the Gentle Rocker 100i device for faster sample recovery from the Next Generation Impactor (NGI). According to Copley, the Gentle Rocker 100i offers controlled agitation of the entire NGI collection cup tray, with agitation speeds from 10 to 60 rpm and a tilting function for easier solution sampling and "enables the … [Read more...] about Copley Scientific launches Gentle Rocker 100i sample recovery system for the NGI
News
Catalent adds nasal spray manufacturing capacity
CDMO Catalent, which offers services for a full range of OINDPs, has announced the completion of the first phase of "a significant expansion" of its development and manufacturing capabilities for unit dose and bi-dose nasal sprays at its facility in Morrisville, NC, USA. The new additions include a high speed micro vial filling line and a high speed assembly line, the … [Read more...] about Catalent adds nasal spray manufacturing capacity
Recipharm launches services for transitioning MDIs to lower-GWP propellants
CDMO Recipharm said that it is now offering services for reformulation of MDIs with new lower global warming potential propellants such as HFA 152a and HFO 1234ze. The company also announced that it has partnered with Prof. Darragh Murnane at the University of Hertfordshire for development of technology around the transition to lower-GWP propellants. The … [Read more...] about Recipharm launches services for transitioning MDIs to lower-GWP propellants
PD study of Opiant’s intranasal nalmefene meets primary endpoint
According to Opiant Pharmaceuticals, a pharmacodynamic study of the company's OPNT003 intranasal nalmefene met its primary endpoint of non-inferiority compared to intranasal naloxone, with 3 mg of OPNT003 almost twice as effective as 4 mg of naloxone in reversing respiratory depression caused by a synthetic opioid at 5 minutes post dose. OPNT003, which is … [Read more...] about PD study of Opiant’s intranasal nalmefene meets primary endpoint
Evoke gets new drug product exclusivity for Gimoti nasal spray
Evoke Pharma announced that the FDA has granted new drug product exclusivity for Gimoti metoclopramide nasal spray, giving the company exclusive marketing rights for 3 following the initial approval date. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. The company also noted that it has two patents covering Gimoti listed in the … [Read more...] about Evoke gets new drug product exclusivity for Gimoti nasal spray
Neurelis gets additional patent covering Valtoco nasal spray
According to Neurelis, the US Patent and Trademark Office (USPTO) has issued a new patent covering Valtoco diazepam nasal spray. The abstract for US Patent No. 11,241,414, titled "Administration of benzodiazepine compositions," says that it "relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for … [Read more...] about Neurelis gets additional patent covering Valtoco nasal spray
Adherium announces the appointment of Francis White as VP of Global Business Development
Inhaler monitoring company Adherium has announced the appointment of Francis White as VP of Global Business Development. White was most recently Managing Director of Olympus Medical in the UK and Ireland and previously held business development roles at AliveCor and Medtronic. Adherium's next generation Hailie inhaler sensor platform received 501(k) clearance in … [Read more...] about Adherium announces the appointment of Francis White as VP of Global Business Development
Virpax reports successful nose-to-brain delivery in a study of VRP324 dry powder CBD in a rodent model
Virpax Pharmaceuticals said that nasal delivery of its VRP324 dry powder cannabidiol in a rodent model produced high concentrations of CBD in the brain. In September 2021, Virpax announced that it had licensed Nanomerics’s molecular envelope technology (MET) for use with VRP324 and that Nanomerics was conducting preclinical studies. Virpax, which is developing the … [Read more...] about Virpax reports successful nose-to-brain delivery in a study of VRP324 dry powder CBD in a rodent model
Firebrick Pharma initiates Phase 2 trial of Nasodine povidone-iodine nasal spray for COVID-19
Australian pharmaceutical company Firebrick Pharma has announced the initiation of a Phase 2 trial of its Nasodine povidone-iodine nasal spray for the reduction of viral shedding in patients with COVID-19. According to Firebrick, a 2001 pilot study with 6 COVID-19 patients demonstrated that a single dose of Nasodine reduced viral shedding by almost 80% one hour post … [Read more...] about Firebrick Pharma initiates Phase 2 trial of Nasodine povidone-iodine nasal spray for COVID-19
Zambon’s CMS I-neb inhaled colistimethate sodium gets Breakthrough Therapy designation
The FDA has granted Breakthrough Therapy designation to Zambon's CMS I-neb colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections, the company said. The FDA had previously granted QIDP and Fast Track designations to the colistimethate sodium powder, which is delivered as a … [Read more...] about Zambon’s CMS I-neb inhaled colistimethate sodium gets Breakthrough Therapy designation